Our August 2025 Clinical Grand Rounds will be on "Widespread Prevalence of Novel Psychoactive Substances and How Traditional Testing Isn’t Always Detecting Them" and will be presented by Jack Kain, PharmD. These presentations are free and open to the public ($10 if requiring CEUs, free CEUs for Root staff). This presentation is 1.5 CEUs.
Jack is the Director of Medical Science Liaison and Drug Monitoring and Toxicology at Quest Diagnostics.
Synopsis and Objectives:
Discussion will include an overview of the various classes of new designer substances appearing across the US, prevalence data pulled from recent laboratory testing and a review of available testing options to identify NPS use and/or exposure.
Questions:
1. What is the most prevalent NPS that we have detected in our clinical specimens?
- Flubromazolam
- Fentanyl
- Xylazine
- Alcohol
2. What type of drug testing methodology is used to identify NPS at Quest?
a. Presumptive
b. Definitive
3. How often does Quest update its NPS test panel without changing the test code?
a. Annually
b. Bi-Annually
c. Never
d. Once a decade
